Background: The karyotypes of 2 patients with abnormal stature and different phenotypes revealed one similar structural abnormality in the X chromosome by conventional cytogenetic studies and fluorescence in situ hybridization analysis (FISH). FISH strongly suggested the presence of two copies of the SHOX gene in the der(X) chromosome. Patients and Results: Patient 1 is a teenager girl with tall stature, behavioral disturbances and normal pubertal development. The abnormal X chromosome was present in all cells studied. Parent’s karyotypes were normal. Patient 2 is a girl with gonadal dysgenesis, mild Turner syndrome phenotype and short stature. The karyotype was a mosaic 45,X/46,X,r(X) and der(X) chromosome presented in most metaphases of the cell lines. Parent’s karyotypes were normal. Nearly all duplication of Xp and partial deletion of the long arm (Xq) from Xq27 or Xq21 to Xqter, in cases 1 and 2, respectively, were observed. In both patients, duplication of Xp translocated to deleted Xq occurred leading to a triplication of the pseudoautosomal region 1 (PAR1) where the SHOX gene is located (Xp22.3). Conclusions: We propose that in some cases of trisomy for the SHOX gene, the effect of overdosage per se may affect the stature, even in patients with preserved ovarian function (case 1), and that estrogen deprivation may not always be a contributor for tall stature (case 2).

Keywords:
Genetic overdosage, Gonadal dysgenesis, Haploinsufficiency, SHOX gene, Psychiatric disturbances, SHOX gene, Tall stature, Turner phenotype, Xp duplication
1.
Barnes IC, Curtis D, Duncan SI: A duplication/deficient X chromosome in a girl with mental retardation and dysmorphic features. J Med Genet 1988;25:264–267.
2.
Ogata T, Kosho T, Wakui K, Fukushima Y, Yoshimoto M, Miharu N: Short stature homeobox-containing gene duplication on the der(X) chromosome in a female with 45,X/46,X,der(X), gonadal dysgenesis and tall stature. J Clin Endocrinol Metab 2000;85:2927–2930.
3.
Binder G, Eggermann T, Enders H, Ranke MB, Dufke A: Tall stature, gonadal dysgenesis and stigmata of Turner’s syndrome caused by a structurally altered X chromosome. J Pediatr 2001;138:285–287.
4.
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkleman M, Nordsieck G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54–63.
5.
Ellison JW, Wardak Z, Young MF, Gehron Robey P, Laig-Webster M, Chiong W: PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum Mol Genet 1997;6:1341–1347.
6.
Kosho T, Muroya K, Nagai T, Fuyimoto M, Yokoya S, Sakamoto H, Hirano T, Terasaki H, Ohashi H, Nishimura G, Sato S, Mattuo N, Ogata T: Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab 1999;84:4613–4621.
7.
Rappold GA, Ross JL, Blaschke RJ, Blum WF: Understanding SHOX deficiency and its role in growth disorders. Abingdon, TMG Healthcare Communications, 2002, p 6.
8.
Shears DJ, Vassal HJ, Goodman FR, Palmer RW, Reardon W, Superti-Furga A, Scambler PJ, Winter RM: Mutation and deletion of the pseudoautosomal gene SHOX cause Léri-Weill dyschondrosteosis. Nat Genet 1998;19:70–73.
9.
Rao E, Weiss B, Fukami M, Mertz A, Meder J, Ogata T, Heinrich U, García-Heras J, Schiebel K, Rappold GA: FISH-deletion mapping defines a 270-kb short stature critical interval in the pseudoautosomal region PAR 1 on human sex chromosomes. Hum Genet 1997;100:236–239.
10.
Liebeszeit BU, Rohrer TR, Singer H, Doerr HG: Tall stature as presenting symptom in a girl with triple X syndrome. J Pediatr Endocrinol Metab 2003;16:233–235.
11.
Lejarraga H, Orfila G: Estándares de peso y estatura para niñas y niños argentinos desde el nacimiento hasta la madurez. Arch Argent Pediatr 1987;85:209.
12.
Moorhead PS, Nowell PC, Mellman WJ, et al: Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960;20:613–616.
13.
Comings DE: Mechanisms of chromosome banding and implications for chromosome structure. Annu Rev Genet 1978;12:25–46.
14.
Sumner AT: A simple technique for demonstrating centromeric heterochromatin. Exp Cell Res 1972;75:304–306.
15.
Dutrillaux B, Lejeune J: Sur une novelle technique d’analyse du caryotype humain. CR Acad Sci [D] (Paris) 1971;272:2638–2640.
16.
Yunis JJ: High resolution of human chromosomes. Science 1976;191:1268–1270.
17.
Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quantitative high-sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1986;83:2934–2938.
18.
Shaffer LG, Slovak ML, Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Basel, Karger, 2009.
19.
Prueitt RL, Ross JL, Zinn AR: Physical mapping of nine Xq translocation breakpoints and identification of XPNPEP2 as a premature ovarian failure candidate gene. Cytogenet Cell Genet 2000;89:44–50.
20.
Lippe B: Turner syndrome. Endocrinol Metab Clin North Am 1991;20:121–152.
21.
Nikolis J, Stolevic E: Recombinant chromosome as a result of pericentric inversion of X chromosome. Hum Genet 1978;45:115–122.
22.
Ogata T, Inokuchi M, Ogawa M: Growth pattern and body proportion in a female with short stature homebox-containing gene overdosage and gonadal estrogen deficiency. Eur J Endocrinol 2002;147:249–254.
23.
Ogata T, Matsuo N, Nishimura G: SHOX haploinsufficiency and overdosage: impact of gonadal function status. J Med Genet 2001;38:1–6.
24.
Nishi MY, Vieira Correa R, Frade Costa EM, Correia Billerbeck AE, Cruzes AL, Domenice S, Carvalho LR, Mendonca BB: Tall stature and poor breast development after estrogen replacement in a hypergonadotrophic patient with a 45,X/46,X,der(X) karyotype with SHOX gene overdosage. Arq Bras Endocrinol Metab 2008;52:1282–1287.
25.
Adamson KA, Cross I, Batch JA, Rappold GA, Glass IA, Ball SG: Trisomy of the short stature homeobox-containing gene (SHOX), resulting from a duplication-deletion of X chromosome. Clin Endocrinol 2002;56:671–675.
26.
Kanaka-Gantenbein C, Kitsiou S, Mavrou A, Stamoyannou L, Kolialexi A, Kekou K, Liakopoulou M, Chrousos G: Tall stature, insulin resistance, and disturbed behavior in a girl with the triple X syndrome harboring three SHOX genes: offspring of a father with mosaic Klinefelter syndrome but with two maternal X chromosomes. Horm Res 2004;61:205–210.
27.
García Estanga P, Mincman J, Coco I, Neuspiller F, Coco R: Anomalía estructural del cromosoma X asociado a falla ovárica prematura. Reproducción 2008;23:35.
28.
Mattei MG, Mattei JF, Vidal I, Giraud F: Structural anomalies of the X-chromosome and inactivation center. Hum Genet 1981;56:401–408.
29.
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, Giros B, Leboyer M, Gillberg C, Bourgeron T, Paris Autism Research International Sibpair Study: Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003;34:27–29.
30.
Melke J, Botros H-G, Chaste P: Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008;13:90–98.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.